Alimera Sciences Inc. (ALIM), having achieved encouraging sales results with both Iluvien and Yutiq in the U.S. market in 2023, is buoyed by the sustained high demand observed in its international markets as well.
Iluvien is a non-bioerodable intravitreal implant indicated for the treatment of diabetic macular edema.
Yutiq, a corticosteroid intravitreal implant, is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Alimera acquired the exclusive global rights to Yutiq excluding China, Hong Kong, Taiwan, Macau, South Korea and Southeast Asia from EyePoint Pharmaceuticals Inc.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.